Welcome to our dedicated page for Atricure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AtriCure, Inc. (ATRC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. AtriCure is a Nasdaq Global Market registrant whose common stock is listed under the symbol ATRC, and its filings offer detailed information on financial performance, capital structure, and material corporate events.
Investors can review Form 8-K current reports in which AtriCure discloses items such as preliminary and quarterly financial results, amendments to its Credit Agreement, and the creation of direct financial obligations. For example, recent 8-K filings describe an amendment to the company’s asset-based revolving credit facility with JPMorgan Chase Bank, N.A., including an extension of the term, a reduction in the overall interest rate, and changes to certain covenants. Other 8-Ks furnish press releases detailing revenue by product category and geography, non-GAAP metrics like adjusted EBITDA and adjusted loss per share, and commentary on operating trends.
Through its periodic reports and related exhibits, AtriCure outlines balance sheet data, income statement details, and non-GAAP reconciliations. These materials help readers understand how the company reports revenue from open ablation, minimally invasive ablation, pain management, and appendage management, as well as its research and development and selling, general, and administrative expenses. The filings also describe the structure and collateral of the ABL Facility, including the security interest in the assets of the borrowers and guarantees by material domestic subsidiaries.
On this page, Stock Titan enhances access to AtriCure’s filings with AI-powered summaries that explain the key points of lengthy documents such as 8-Ks and, when available, 10-Q and 10-K reports. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly, while AI-generated highlights can help users quickly identify important changes in credit agreements, financial guidance, or operating results without reading every line of the original filing.
For those tracking ATRC, this filings hub is a central resource for analyzing the company’s disclosed financial condition, capital arrangements, and significant events as reported in its official SEC documents.
AtriCure, Inc. reported strong growth for the fourth quarter and full year 2025 while moving toward sustained profitability. Fourth quarter 2025 revenue was $140.5 million, up 13.1% year over year, with net income of $1.8 million and adjusted EBITDA of $19.9 million. Full year 2025 revenue reached $534.5 million, an increase of 14.9%, and gross margin improved to 75.0%. The company narrowed its net loss to $11.4 million while nearly doubling adjusted EBITDA to $61.8 million. Management projects 2026 revenue of $600–$610 million, full year positive net income, and adjusted EBITDA of $80–$82 million, with expected adjusted EPS between $0.09 and $0.15 and GAAP EPS between $0.00 and $0.04.
Hood River Capital Management LLC filed Amendment No. 2 to a Schedule 13G reporting its beneficial ownership of AtriCure, Inc. common stock. The firm reports holding 3,096,611 shares, representing 6.23% of the outstanding common stock as of the event date.
Hood River discloses sole power to dispose of these 3,096,611 shares but no power to vote them. It certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of AtriCure.
AtriCure, Inc. entered into a First Amendment to its credit agreement with JPMorgan Chase Bank and other lenders, extending the term of its asset-based revolving credit facility by three years. The amended credit agreement maintains an asset-based revolving credit facility of up to
AtriCure, Inc. President, CEO, and Director Michael H. Carrel reported a charitable gift of 4,000 shares of AtriCure common stock on 12/10/2025. The transfer is coded as a gift and recorded at a price of $0, reflecting that no consideration was received for the donation. After this transaction, he beneficially owns 687,377 shares directly, with an additional 9,310 shares held by his children and 2,250 shares held by his parents, which he reports as indirect holdings while disclaiming beneficial ownership except for his pecuniary interest.
AtriCure, Inc. (ATRC) director reports option exercises and share sales. On 11/24/2025, the reporting person exercised 5,033 non-qualified stock options at $19.95 per share and sold 5,033 shares of common stock at a weighted average price of $37.32 per share. On 11/25/2025, they exercised an additional 4,967 options at $19.95 and sold 4,967 shares at $38.00 per share.
After these transactions, the director beneficially owned 34,374 shares of AtriCure common stock directly and held 25,000 non-qualified stock options. The options exercised on these dates were originally granted on November 11, 2016 and vest over four years, with 25% after one year and the remainder in monthly installments over the next three years.
AtriCure, Inc. (ATRC) reported an insider stock transaction by its Chief Marketing & Strategy Officer. On 11/26/2025, the officer sold 5,166 shares of AtriCure common stock in an open market transaction coded "S" for sale.
The reported sale price is a weighted average of $37.29 per share, with individual trades executed at prices ranging from $36.51 to $38.44 per share. After this transaction, the officer beneficially owns 78,798 shares of AtriCure common stock, held directly.
AtriCure, Inc. (ATRC) reported an insider share sale by a director. On 11/21/2025, the reporting person sold 3,000 shares of AtriCure common stock in an open-market transaction coded as a sale. The weighted average sale price was $35.72 per share, with individual trade prices ranging from $35.71 to $35.76.
Following this transaction, the director beneficially owns 11,371 AtriCure shares, held directly. The filing notes that detailed trade data for the individual prices and share amounts within the reported range will be provided upon request to the SEC staff, the issuer, or any security holder.
AtriCure, Inc. CEO and President Michael H. Carrel, who also serves as a director, reported a charitable gift of 6,000 shares of AtriCure common stock on 11/13/2025, according to a Form 4 filing. The transaction used code “G,” indicating a gift, and was reported at a price of $0, with the filing noting that no consideration was received for this transfer.
After the reported transaction, Carrel beneficially owns 691,377 shares of AtriCure common stock directly. The filing also lists 9,310 shares held indirectly through his children and 2,250 shares held indirectly through his parents, with a statement that he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.
AtriCure (ATRC) reported solid third‑quarter growth and near break‑even results. Revenue rose to $134,269, up 15.8% year over year, with gross margin at 75.5% versus 74.9% a year ago. Operating income was $208, and net loss narrowed to $267, or $0.01 per share. For the first nine months, revenue reached $394,028, up 15.5%.
Growth was led by appendage management and pain management in the United States, while minimally invasive ablation declined as physicians shifted procedures. Cash and cash equivalents were $147,865 with long‑term debt of $61,865 and unused ABL borrowing availability of $61,885 as of September 30, 2025. The company completed enrollment of 6,500 patients in the LeAAPS trial and launched the cryoICE cryoXT probe for amputation pain therapy in the U.S. A sale‑and‑leaseback of a building resulted in a $6,250 financing obligation. Shares outstanding were 49,716,988 as of October 27, 2025.
AtriCure, Inc. (ATRC) filed an Amendment No. 1 to its Form 8-K to add the required signature of a duly authorized representative. The amendment makes no other changes to the original report filed on October 29, 2025.
The company also noted it issued a press release regarding financial results for the third quarter ended September 30, 2025, and scheduled a conference call on October 29, 2025 at 4:30 p.m. Eastern Time. The press release is furnished as Exhibit 99.1.